Pancreatic Cancer Research

ResearcherShanghai Medical College of Fudan UniversityActive in the last 2 years

Lei Wang

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-6604-3175; OpenAlex author ID A5100435747, A5123178809. Sources: OpenAlex.

Their work

Papers
41 (first author 11, last author 2)
Trials
0
Grants
0
Labs led
0
Collaborators
138
Papers, trials and grants by year

2013: 4 papers · 2014: 1 paper · 2015: none · 2016: 2 papers · 2017: 7 papers · 2018: 4 papers · 2019: 1 paper · 2020: 3 papers · 2021: 4 papers · 2022: 8 papers · 2023: 3 papers · 2024: 2 papers · 2025: 1 paper · 2026: 1 paper

Papers 41

  1. Diagnostic efficacy of blood biomarkers for differentiating early-stage pancreatic cancer from chronic pancreatitis: A systematic review and network meta-analy… Co-author DOI 10.1016/j.tranon.2026.102674↗
  2. Hydrogel PCDME creates pancreatic cancer stem cells in OXPHOS metabolic state with TXNIP elevation. First author DOI 10.1016/j.bbrc.2025.151416↗
  3. Activation of the PI3K/AKT signaling pathway by ARNTL2 enhances cellular glycolysis and sensitizes pancreatic adenocarcinoma to erlotinib. Co-author DOI 10.1186/s12943-024-01965-5↗
  4. Evaluating the benefits of adjuvant chemotherapy in patients with pancreatic cancer undergoing radical pancreatectomy after neoadjuvant therapy-a systematic re… Co-author DOI 10.3389/fonc.2024.1429386↗
  5. Single cell transcriptomic analyses implicate an immunosuppressive tumor microenvironment in pancreatic cancer liver metastasis. Co-author DOI 10.1038/s41467-023-40727-7↗
  6. Fibrinogen-to-prealbumin ratio: A new prognostic marker of resectable pancreatic cancer. Co-author DOI 10.3389/fonc.2023.1149942↗
  7. COL12A1 Acts as a Novel Prognosis Biomarker and Activates Cancer-Associated Fibroblasts in Pancreatic Cancer through Bioinformatics and Experimental Validation. First author DOI 10.3390/cancers15051480↗
  8. A panel of necroptosis-related genes predicts the prognosis of pancreatic adenocarcinoma. First author DOI 10.1016/j.tranon.2022.101462↗
  9. Molecular signatures of tumor progression in pancreatic adenocarcinoma identified by energy metabolism characteristics. Co-author DOI 10.1186/s12885-022-09487-3↗
  10. Targeting CRABP-II overcomes pancreatic cancer drug resistance by reversing lipid raft cholesterol accumulation and AKT survival signaling. First author DOI 10.1186/s13046-022-02261-0↗
  11. Molecular Landscape and Prognostic Biomarker Analysis of Advanced Pancreatic Cancer and Predictors of Treatment Efficacy of AG Chemotherapy. Co-author DOI 10.3389/fonc.2022.844527↗
  12. Study protocol for a prospective, open-label, single-arm, phase II study on the combination of tislelizumab, nab-paclitaxel, gemcitabine, and concurrent radiot… Co-author DOI 10.3389/fonc.2022.879661↗
  13. Case Report: Pathologic Complete Response to Induction Therapy in a Patient With Potentially Resectable Pancreatic Cancer. Co-author DOI 10.3389/fonc.2022.898119↗
  14. The effect of minimally invasive or open radical antegrade modular pancreatosplenectomy on pancreatic cancer: A multicenter randomized clinical trial protocol. Co-author DOI 10.3389/fonc.2022.965508↗
  15. A TP53-associated immune prognostic signature for the prediction of the overall survival and therapeutic responses in pancreatic cancer. Last author DOI 10.3934/mbe.2022010↗
  16. SPINK1 mutations and risk of pancreatic cancer in a Chinese cohort. Co-author DOI 10.1016/j.pan.2021.05.304↗
  17. Analysis of T-cell receptor repertoire in peripheral blood of patients with pancreatic cancer and other pancreatic diseases. Co-author DOI 10.1111/jcmm.16358↗
  18. Endoscopic Ultrasound-Guided Acquisition of Portal Venous Circulating Tumor Cells as a Potential Diagnostic and Prognostic Tool for Pancreatic Cancer. Co-author DOI 10.2147/cmar.s330473↗
  19. Neoadjuvant therapy for pancreatic cancer: Limitations and advances of response assessment (Review). Last author DOI 10.3892/or.2021.7977↗
  20. Signaling adaptor protein Crk is involved in malignant feature of pancreatic cancer associated with phosphorylation of c-Met. First author DOI 10.1016/j.bbrc.2020.01.105↗
  21. Genome-Wide Analysis of Cell-Free DNA Methylation Profiling for the Early Diagnosis of Pancreatic Cancer. First author DOI 10.3389/fgene.2020.596078↗
  22. ALDH1A3 Accelerates Pancreatic Cancer Metastasis by Promoting Glucose Metabolism. Co-author DOI 10.3389/fonc.2020.00915↗
  23. Retraction Note to: Excessive mitochondrial fragmentation triggered by erlotinib promotes pancreatic cancer PANC‑1 cell apoptosis via activating the mROS‑HtrA2… Co-author DOI 10.1186/s12935-019-1019-3↗
  24. Immunotherapy for pancreatic cancer: A long and hopeful journey. First author DOI 10.1016/j.canlet.2018.03.040↗
  25. Clinical significance of MUC13 in pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.hpb.2017.12.003↗
  26. MicroRNA-30b targets Snail to impede epithelial-mesenchymal transition in pancreatic cancer stem cells. Co-author DOI 10.7150/jca.25006↗
  27. Prognostic values of common clinical parameters in advanced pancreatic ductal adenocarcinoma: a large multicenter cohort study of ten years. Co-author PMID 29641971↗
  28. Neoadjuvant therapy in pancreatic cancer: a systematic review and meta-analysis of prospective studies. Co-author DOI 10.1002/cam4.1071↗
  29. Early detection of pancreatic cancer: Where are we now and where are we going? Co-author DOI 10.1002/ijc.30670↗
  30. Crosstalk between stromal cells and cancer cells in pancreatic cancer: New insights into stromal biology. Co-author DOI 10.1016/j.canlet.2017.01.041↗
  31. Development and Validation of a Nomogram for Predicting Survival in Patients with Advanced Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1038/s41598-017-11227-8↗
  32. Apatinib concurrent gemcitabine for controlling malignant ascites in advanced pancreatic cancer patient: A case report. First author DOI 10.1097/md.0000000000008725↗
  33. Risk factors of liver metastasis from advanced pancreatic adenocarcinoma: a large multicenter cohort study. First author DOI 10.1186/s12957-017-1175-7↗
  34. A SLC24A2 Gene Variant Uncovered in Pancreatic Ductal Adenocarcinoma by Whole Exome Sequencing. Co-author DOI 10.1620/tjem.241.287↗
  35. Is chronic hepatitis B infection a protective factor for the progression of advanced pancreatic ductal adenocarcinoma? An analysis from a large multicenter coh… Co-author DOI 10.18632/oncotarget.13000↗
  36. A positive feedback loop of p53/miR-19/TP53INP1 modulates pancreatic cancer cell proliferation and apoptosis. First author DOI 10.3892/or.2015.4361↗
  37. MiR-200a inhibits epithelial-mesenchymal transition of pancreatic cancer stem cell. Co-author DOI 10.1186/1471-2407-14-85↗
  38. High level of FOXC1 expression is associated with poor prognosis in pancreatic ductal adenocarcinoma. Co-author DOI 10.1007/s13277-012-0617-7↗
  39. CIP2A expression is associated with altered expression of epithelial-mesenchymal transition markers and predictive of poor prognosis in pancreatic ductal adeno… Co-author DOI 10.1007/s13277-013-0775-2↗
  40. Knockdown of Oct4 and Nanog expression inhibits the stemness of pancreatic cancer cells. Co-author DOI 10.1016/j.canlet.2013.07.009↗
  41. MiR-21 upregulation induced by promoter zone histone acetylation is associated with chemoresistance to gemcitabine and enhanced malignancy of pancreatic cancer… First author DOI 10.7314/apjcp.2013.14.12.7529↗

Closest collaborators

The 25 strongest of 138 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Jianwei Xu · 7 shared papers, 2017–2023 · strength 0.78
  2. Sanyuan Hu · 5 shared papers, 2017–2021 · strength 0.49
  3. Xiaoping Zou · 4 shared papers, 2020–2023 · strength 0.46
  4. Wen‐Bin Zou · 2 shared papers, 2021–2026 · strength 0.42
  5. Zhuan Liao · 2 shared papers, 2021–2026 · strength 0.42
  6. Chengqing Li · 2 shared papers, 2023–2024 · strength 0.37
  7. Changchang Lu · 3 shared papers, 2022 · strength 0.37
  8. Yudong Qiu · 3 shared papers, 2022 · strength 0.37
  9. Xin Qiu · 3 shared papers, 2022 · strength 0.37
  10. Qi Li · 3 shared papers, 2022 · strength 0.37
  11. Baorui Liu · 3 shared papers, 2022 · strength 0.37
  12. Shinya Tanaka · 2 shared papers, 2020–2025 · strength 0.36
  13. Satoshi Hirano · 2 shared papers, 2020–2025 · strength 0.36
  14. Shanshan Shen · 3 shared papers, 2020–2023 · strength 0.35
  15. Shu Zhang · 3 shared papers, 2020–2023 · strength 0.34
  16. Zhao‐Shen Li · 4 shared papers, 2016–2021 · strength 0.32
  17. Ying Lv · 3 shared papers, 2020–2021 · strength 0.32
  18. Yuhua Lu · 3 shared papers, 2013–2023 · strength 0.31
  19. Di Wu · 1 shared paper, 2026 · strength 0.29
  20. Yuma Aoki · 1 shared paper, 2025 · strength 0.26
  21. Hanxiang Zhan · 2 shared papers, 2017–2021 · strength 0.25
  22. Linxi Zhu · 2 shared papers, 2022 · strength 0.25
  23. Juan Du · 2 shared papers, 2022 · strength 0.25
  24. Jun Chen · 2 shared papers, 2022 · strength 0.25
  25. Guangyong Zhang · 3 shared papers, 2017–2018 · strength 0.25

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.